Pictured: Pneumowave
PneumoWave is a development-stage remote monitoring platform for patients at risk of Opioid Induced Respiratory Depression (OIRD.) It aims to continuously monitor and accurately detect respiratory depression, generating an alert.
Designed to detect OIRD caused by either prescription or illicit drugs, whether in a healthcare facility or at home, its aim is to stop all preventable deaths from opioid use.
Together we developed a proof-of-concept where physicians can enroll patients in remote respiratory monitoring. This includes a dashboard for viewing repiratory data and mobile app prototype that demonstrates how patients can activate monitoring and trigger an alert if they experiencing dangerous breathing activity.
Towards the end of the 20th century, misinformation by a number of pharmaceutical companies stating that their opioid painkilling products were not addictive led to a surge in prescribing across the USA for patients with chronic pain.
At the same time, wider availability led to an increase in the number of people with emotional trauma and mental health conditions turning to opioids for their euphoric effects and becoming rapidly dependent.
Misuse of prescription and illicitly manufactured opioids is now the largest cause of death in most developed countries. In the USA, the result is a public health emergency that killed more than 70,000 people last year (CDC).
* https://wonder.cdc.gov/
Narcan and Naloxone nasal sprays
OIRD occurs when ventilation is inadequate to perform needed respiratory gas exchange. By definition it causes an increased concentration of carbon dioxide and respiratory acidosis.
Time is critical when OIRD occurs. Respiratory activity weakens and slows to a creep; the blood is starved for oxygen and poisoned by carbon dioxide. Emergency personnel will often administer narcan and oxygen.
Every second lost risks brain cells or someone's life.
Credit: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.15580
PneumoWave is a remote monitoring platform for patients at risk of OIRD. It aims to continuously monitor and accurately detect respiratory depression.
Using a wearable sensor, respiratory activity is recorded and monitored remotely, generating an alert if dangerous respiratory activity is detected.
Designed to detect OIRD caused by either prescription or illicit drugs, whether in a healthcare facility or at home, its aim is to stop all preventable deaths from opioid use.
Together, we developed a proof-of-concept where physicians can enroll patients in remote respiratory monitoring. This includes a dashboard for viewing repiratory data and mobile app prototype that demonstrates how patients can activate monitoring that allows for emergency services to be notified if they experience OIRD.
We started by creating a database for storing respiratory data. Then we created patient onboarding. The physicians could then prescribe a Pneumowave sensor and assign it to the patient.
We created a web app for viewing real-time respiratory data in a dashboard.
The doctors and patients can also test the system this way.
Finally, we designed a mobile app that patients could use to activate monitoring sessions.
We submitted the prototype to a usability study and sought feedback from patients, physicians, opinion leaders and stakeholders.
A physician can login to their dashboard and view all their patients. When they prescribe a Pnuemowave sensor to a patient, the device is able to transmit respiratory data to the cloud.
A physician can login to their dashboard and view all their patients. When they prescribe a Pnuemowave sensor to a patient, the device is able to transmit respiratory data to the cloud.
A physician can login to their dashboard and view all their patients. When they prescribe a Pnuemowave sensor to a patient, the device is able to transmit respiratory data to the cloud.
A physician can login to their dashboard and view all their patients. When they prescribe a Pnuemowave sensor to a patient, the device is able to transmit respiratory data to the cloud.
A physician can login to their dashboard and view all their patients. When they prescribe a Pnuemowave sensor to a patient, the device is able to transmit respiratory data to the cloud.
Stigmas surrounding drug use. Conflicted users. Understanding change aversion.
What can a user do? What if they are impaired?
Some people take opiates for injuries or recovering from medical procedures. They may not have full mobility.
Is the product easy to use? Does it feel familiar? Which patterns should the product follow?
Users that are concerned about discretion.
Is it possible to make this a reality?
Pneumowave was founded in 2018 with the aim of preventing serious adverse effects caused by conditions affecting the respiratory system.
Their primary focus is on preventing deaths and reducing hospital admissions by capturing and analysing real-time physiological signals.
Pneumowave is currently undergoing clinical development and evaluation in an international program of research, working to make PneumoWave widely available, as soon as possible, via the FDA Breakthrough Medical Device Program.
PneumoWave’s technology is currently undergoing development and evaluation in clinical trials. Performance characteristics have yet to be established.
PneumoWave is a development-stage remote monitoring platform for patients at risk of Opioid Induced Respiratory Depression (OIRD.) It aims to continuously monitor and accurately detect respiratory depression, generating an alert. Designed to detect OIRD caused by either prescription or illicit drugs, whether in a healthcare facility or at home, their aim is to stop all preventable deaths from opioid use.